antibody-drug conjugates in advanced urothelial cancer: sacituzumab govitecan
Published 5 years ago • 96 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
0:44
antibody-drug conjugates for advanced bladder cancer
-
1:32
antibody-drug conjugates in urothelial carcinoma
-
2:30
the future of antibody-drug conjugates in urothelial cancer
-
4:21
sacituzumab govitecan plus enfortumab vedotin in advanced urothelial cancer
-
40:12
improving patient outcomes in urothelial carcinoma with novel antibody–drug conjugates
-
2:02
sacituzumab govitecan in the treatment of metastatic urothelial carcinoma
-
31:39
the evolving role of antibody-drug conjugates in the treatment of urothelial carcinoma
-
6:17
antibody-drug conjugates in tnbc: sacituzumab govitecan
-
27:03
antibody drug conjugates: the end of chemotherapy | 2023 west oncology conference
-
13:18
updates in the management of lung cancer with adcs
-
8:45
how are antibody drug conjugates used to treat breast cancer? all you need to know
-
0:55
adcs for advanced urothelial carcinoma
-
0:30
enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma
-
1:49
final os analysis of sacituzumab govitecan in tropics-02
-
2:38
trophy-u-01 cohort 3: sacituzumab govitecan pembrolizumab for patients with muc
-
7:09
understanding antibody drug conjugates
-
2:16
efficacy of sacituzumab govitecan by trop-2 expression in patients with muc
-
0:58
adcs in the management of urothelial carcinoma
-
1:59
sacituzumab govitecan and nktr-214 plus nivolumab for bladder cancer
-
6:01
sacituzumab govitecan given accelerated fda approval for advanced urothelial cancer
-
1:13
phase iii tropics-04 trial: sacituzumab govitecan vs treatment of choice in advanced muc
-
2:57
efficacy of sacituzumab govitecan in muc by trop-2 expression